Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20754232 | 0.74 | IMPDH2 (0.50) | CYP4F2CYP4A11ALDH1A1GAADPP4 | |
| SCHEMBL15811503 | 0.72 | CNKSR1 (0.62) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL14874444 | 0.72 | CYP4F2 (0.48) | CYP4F2CYP4A11ALDH1A1GAADPP4 | |
| SCHEMBL10607777 | 0.70 | CYP3A4 (0.65) | CYP4F2CYP4A11ALDH1A1KMT2AMEN1 | |
| SCHEMBL8472221 | 0.69 | CYP4F2 (0.46) | CYP4F2CYP4A11ALDH1A1GAAKDM4E | |
| SCHEMBL491048 | 0.69 | CYP1A2 (0.55) | CYP4F2CYP4A11ALDH1A1DPP4KMT2A | |
| SCHEMBL17722574 | 0.69 | CYP4F2 (0.54) | CYP4F2CYP4A11ALDH1A1GAADPP4 | |
| SCHEMBL11210532 | 0.69 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1GAADPP4 | |
| SCHEMBL3492958 | 0.69 | ALDH1A1 (0.53) | CYP4F2CYP4A11ALDH1A1GAAKMT2A | |
| SCHEMBL14874587 | 0.69 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1GAADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340532-B2 | Methods and compositions for inhibiting CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | PHUSIS THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307482-A1 | METHODS AND COMPOSITIONS FOR INHIBITING CNKSR1 | CNKSR1, CAMKK1, CAMKK2 | CYP4F2 3877/4885CYP4A11 3758/4885ALDH1A1 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.